• $3 million R&D Tax Incentive Refund received for FY25 R&D activities
• Adds to Microba's strong financial position of $13.9 million in cash or equivalents at end of Q1 FY26
• R&D Tax Incentive program vital in accelerating innovation across Microba's gastrointestinal diagnostics and clinical stage therapeutics pipeline

Microba Life Sciences Limited (ASX: MAP), a company at the forefront of health and human care, has announced that it has received a $3,063,625 Research & Development (R&D) Tax Incentive refund relating to R&D activities completed in the 2024/2025 financial year. The Australian Government's R&D Tax Incentive program provides companies with a 43.5% refundable tax offset for eligible R&D activities. Microba's Chief Executive Officer, Dr. Luke Reid, commented that the program continues to be vital in assisting Microba to accelerate innovation across its gastrointestinal diagnostics portfolio and in FY25 to advance its clinical stage therapeutics pipeline. These research and development outputs are continuously being translated into Microba's advanced clinical products, delivering transformative health outcomes and changing lives for thousands of people across Australia and the globe. The $3 million R&D Tax Incentive refund adds to Microba's strong financial position, with the company reporting $13.9 million in cash or equivalents at the end of Q1 FY26.